Aroa Biosurgery Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Aroa Biosurgery wird ein jährliches Gewinn- und Umsatzwachstum von 49.5% bzw. 12.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 49.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.2% betragen.
Wichtige Informationen
49.5%
Wachstumsrate der Gewinne
49.32%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 39.1% |
| Wachstumsrate der Einnahmen | 12.5% |
| Zukünftige Eigenkapitalrendite | 12.20% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 29 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...Recent updates
ARX: Positive Wound Trial Results Will Support Stronger Future Profitability
Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).
Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?
Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, trauma, burns and reconstructive surgery. What are the underlying business or industry changes driving this perspective?Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...
Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence
Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Unfortunately for some shareholders, the Aroa Biosurgery Limited ( ASX:ARX ) share price has dived 26% in the last...Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%
Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders that were waiting for something to happen have been dealt a blow with...Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 4.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Shareholders in Aroa Biosurgery Limited ( ASX:ARX ) may be thrilled to learn that the analysts have just delivered a...Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Does the October share price for Aroa Biosurgery Limited ( ASX:ARX ) reflect what it's really worth? Today, we will...We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
Investors in Aroa Biosurgery Limited ( ASX:ARX ) had a good week, as its shares rose 6.2% to close at AU$1.20 following...An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Aroa Biosurgery...Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?
A look at the shareholders of Aroa Biosurgery Limited ( ASX:ARX ) can tell us which group is most powerful...Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)
Anyone interested in Aroa Biosurgery Limited ( ASX:ARX ) should probably be aware that the Independent Non-Executive...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2029 | 158 | 18 | 16 | 21 | 3 |
| 3/31/2028 | 139 | 12 | 16 | 16 | 3 |
| 3/31/2027 | 121 | 4 | 9 | 12 | 3 |
| 3/31/2026 | 104 | 5 | 7 | 11 | N/A |
| 12/31/2025 | 97 | 1 | 5 | 8 | N/A |
| 9/30/2025 | 90 | -2 | 3 | 6 | N/A |
| 6/30/2025 | 88 | -3 | -2 | 2 | N/A |
| 3/31/2025 | 85 | -4 | -6 | -3 | N/A |
| 12/31/2024 | 81 | -6 | -9 | -4 | N/A |
| 9/30/2024 | 76 | -8 | -11 | -5 | N/A |
| 6/30/2024 | 73 | -9 | -13 | -6 | N/A |
| 3/31/2024 | 69 | -11 | -14 | -7 | N/A |
| 12/31/2023 | 67 | -9 | -15 | -7 | N/A |
| 9/30/2023 | 66 | -8 | -15 | -6 | N/A |
| 6/30/2023 | 65 | -4 | -13 | -5 | N/A |
| 3/31/2023 | 63 | 0 | -11 | -4 | N/A |
| 12/31/2022 | 57 | -1 | -13 | -7 | N/A |
| 9/30/2022 | 51 | -2 | -15 | -10 | N/A |
| 6/30/2022 | 45 | -5 | -16 | -11 | N/A |
| 3/31/2022 | 40 | -8 | -16 | -12 | N/A |
| 12/31/2021 | 35 | -10 | -14 | -10 | N/A |
| 9/30/2021 | 31 | -11 | -11 | -8 | N/A |
| 6/30/2021 | 27 | -15 | -9 | -6 | N/A |
| 3/31/2021 | 22 | -19 | -7 | -5 | N/A |
| 12/31/2020 | 22 | -19 | -6 | -5 | N/A |
| 9/30/2020 | 21 | -19 | -6 | -4 | N/A |
| 6/30/2020 | 23 | -12 | -3 | -1 | N/A |
| 3/31/2020 | 25 | -6 | 0 | 2 | N/A |
| 3/31/2019 | 24 | 1 | N/A | 0 | N/A |
| 3/31/2018 | 11 | -1 | N/A | -3 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: ARXDas prognostizierte Gewinnwachstum (49.5% pro Jahr) liegt über der Sparquote (3.6%).
Ertrag vs. Markt: ARXDie Erträge des Unternehmens (49.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (12.1% pro Jahr).
Hohe Wachstumserträge: ARXEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: ARXDie Einnahmen des Unternehmens (12.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (6.3% pro Jahr).
Hohe Wachstumseinnahmen: ARXDie Einnahmen des Unternehmens (12.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: ARXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12.2%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/04 03:06 |
| Aktienkurs zum Tagesende | 2026/06/04 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Aroa Biosurgery Limited wird von 4 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| John Hester | Bell Potter |
| Shane Storey | Canaccord Genuity |
| Scott Power | Morgans Financial Limited |